Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Summary

The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.

Timeline

Start

2025-05-27

Primary completion

2029-04

Completion

2029-04

Drugs

Indications